Cadila Healthcare, a Rs. 7,200 crore pharma major from Ahmedabad, has posted impressive financial performance during the third quarter ended December 2014 and its consolidated net profit went up sharply by 51.6 per cent to Rs. 282 crore from Rs. 186 crore in the corresponding period of last year. EBDITA also improved by 48.4 per cent to Rs. 457 crore from Rs. 308 crore. The company's consolidated net sales grew by 17.7 per cent to Rs. 2,160 crore from Rs. 1,836 crore. With significant jump in profits, its EPS improved to Rs. 13.77 from Rs. 9.08 in the last period. After the announcement of strong financial results, Cadila scrip moved up by Rs. 22 to Rs. 1,505 on BSE.

Its business in US registered a growth of 42 per cent and emerging markets business grew by 23 per cent. It filed 5 additional ANDAs with the US FDA taking the cumulative ANDA filings to 255. The group's R&D pipeline which comprises 25 biologies (including novel biologies), is being developed to treat auto immune disorders like arthritis, cancer, in fertility and stroke.

The company launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis, Exemptia is given as a 40 mg subcutaneous injection once every alternate week. The therapy is currently marketed by Zydus Biovation – a new division launched to exclusively market this ground breaking therapy.

For the nine months period ended December 2014, Cadila's consolidated net sales increased by 21 per cent to Rs. 6,361 crore from Rs. 5,256 crore in the similar period of last year. Its net profit went up by 41.8 per cent to Rs. 800 crore from Rs. 564 crore. Employees cost increased by 12 per cent to Rs. 894 crore from Rs. 798 crore. The company reduced its interest cost by 22 per cent to Rs. 51.58 crore from Rs. 66.15 crore.

Cadila's standalone net sales for the nine months ended December 2014 went up by 32.2 per cent to Rs. 3,349 crore from Rs. 2,534 crore in the same period of last year and its net profit moved up by 34.5 per cent to Rs. 924 crore from Rs. 687 crore.